Hydrogen treatment: a novel option in liver diseases.
Jian Shi, Brittany Duncan, Xuyuan Kuang · Clinical medicine (London, England) · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined the available evidence on molecular hydrogen. The reviewed evidence supports molecular hydrogen's therapeutic potential. Additional well-designed studies are needed to clarify clinical safety and effectiveness.
What the Review Examined
The review examined hydrogen treatment: a novel option in liver diseases.
Main Findings Across the Literature
Hydrogen therapy is a very promising treatment against several diseases due to its mild attributes, high affinity and inherent biosafety. However, there is little elaboration about current hydrogen treatment in liver diseases. The major focus is clinical hydrogen use and related mechanisms in liver dysfunction or diseases, including non-alcoholic fatty liver disease, hepatitis B, liver dysfunction caused by liver tumour and colorectal tumour chemotherapy.
H₂ Mechanisms / Biological Findings
The major focus is clinical hydrogen use and related mechanisms in liver dysfunction or diseases, including non-alcoholic fatty liver disease, hepatitis B, liver dysfunction caused by liver tumour and colorectal tumour chemotherapy.
Authors’ Conclusion
A distinct authors’ conclusion was not available in the source material reviewed by H2HUBB.